ES2246105B1 - Uso de anticuerpos para el tratamiento de enfermedades amiloideas. - Google Patents

Uso de anticuerpos para el tratamiento de enfermedades amiloideas. Download PDF

Info

Publication number
ES2246105B1
ES2246105B1 ES200301054A ES200301054A ES2246105B1 ES 2246105 B1 ES2246105 B1 ES 2246105B1 ES 200301054 A ES200301054 A ES 200301054A ES 200301054 A ES200301054 A ES 200301054A ES 2246105 B1 ES2246105 B1 ES 2246105B1
Authority
ES
Spain
Prior art keywords
peptide
amyloid
disease
antibody
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200301054A
Other languages
English (en)
Spanish (es)
Other versions
ES2246105A1 (es
Inventor
Jose Manuel Sarasa Barrio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Araclon Biotech SL
Original Assignee
Araclon Biotech SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Araclon Biotech SL filed Critical Araclon Biotech SL
Priority to ES200301054A priority Critical patent/ES2246105B1/es
Priority to ES200403158A priority patent/ES2246177B1/es
Priority to ES200403159A priority patent/ES2246178B1/es
Priority to DK04730882T priority patent/DK1623719T3/da
Priority to ES10012342T priority patent/ES2423590T3/es
Priority to EP08170207A priority patent/EP2082747A3/en
Priority to DK10012342.1T priority patent/DK2356996T5/da
Priority to EP08170222.7A priority patent/EP2075007B9/en
Priority to PT04730882T priority patent/PT1623719E/pt
Priority to PL10012342T priority patent/PL2356996T3/pl
Priority to DK08170222.7T priority patent/DK2075007T3/da
Priority to CNA2004800125340A priority patent/CN1784240A/zh
Priority to RU2005134351/15A priority patent/RU2385161C2/ru
Priority to JP2006505607A priority patent/JP2006525288A/ja
Priority to DE602004021797T priority patent/DE602004021797D1/de
Priority to EP04730882A priority patent/EP1623719B1/en
Priority to PT81702227T priority patent/PT2075007E/pt
Priority to BRPI0410684-9A priority patent/BRPI0410684A/pt
Priority to EP10012342.1A priority patent/EP2356996B9/en
Priority to AU2004237373A priority patent/AU2004237373A1/en
Priority to MXPA05010914A priority patent/MXPA05010914A/es
Priority to ES04730882T priority patent/ES2329369T3/es
Priority to CNA2008100898940A priority patent/CN101264326A/zh
Priority to US10/555,865 priority patent/US20090162362A1/en
Priority to PCT/ES2004/000194 priority patent/WO2004098631A1/es
Priority to PL08170222T priority patent/PL2075007T3/pl
Priority to AT04730882T priority patent/ATE435024T1/de
Priority to EP10012340A priority patent/EP2305286A3/en
Priority to CA2524571A priority patent/CA2524571C/en
Priority to PL04730882T priority patent/PL1623719T3/pl
Priority to PT100123421T priority patent/PT2356996E/pt
Priority to ES08170222T priority patent/ES2423281T3/es
Priority to SI200431235T priority patent/SI1623719T1/sl
Priority to IL171651A priority patent/IL171651A/en
Publication of ES2246105A1 publication Critical patent/ES2246105A1/es
Application granted granted Critical
Publication of ES2246105B1 publication Critical patent/ES2246105B1/es
Priority to CY20091101026T priority patent/CY1109454T1/el
Priority to RU2009148539/15A priority patent/RU2526155C2/ru
Priority to IL207881A priority patent/IL207881A/en
Priority to IL207876A priority patent/IL207876A/en
Priority to IL207878A priority patent/IL207878A/en
Priority to IL207877A priority patent/IL207877A/en
Priority to IL207879A priority patent/IL207879A/en
Priority to IL207875A priority patent/IL207875A/en
Priority to IL207880A priority patent/IL207880A/en
Priority to AU2011200170A priority patent/AU2011200170C1/en
Priority to US13/050,654 priority patent/US20110262458A1/en
Priority to JP2011191515A priority patent/JP2012006967A/ja
Priority to US14/026,374 priority patent/US20140044725A1/en
Priority to JP2014038360A priority patent/JP2014129389A/ja
Priority to JP2016003772A priority patent/JP2016065100A/ja
Priority to US15/602,779 priority patent/US20170260234A1/en
Priority to JP2018088643A priority patent/JP2018119011A/ja
Priority to US16/745,067 priority patent/US20200140488A1/en
Priority to US17/213,720 priority patent/US20210214394A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
ES200301054A 2003-05-08 2003-05-08 Uso de anticuerpos para el tratamiento de enfermedades amiloideas. Expired - Fee Related ES2246105B1 (es)

Priority Applications (53)

Application Number Priority Date Filing Date Title
ES200301054A ES2246105B1 (es) 2003-05-08 2003-05-08 Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
ES200403158A ES2246177B1 (es) 2003-05-08 2003-05-08 Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
ES200403159A ES2246178B1 (es) 2003-05-08 2003-05-08 Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
DK04730882T DK1623719T3 (da) 2003-05-08 2004-05-03 Behandling af Alzheimers sygdom og cerebral amyloid angiopati
ES10012342T ES2423590T3 (es) 2003-05-08 2004-05-03 Tratamiento de la enfermedad de Alzheimer
EP08170207A EP2082747A3 (en) 2003-05-08 2004-05-03 Treatment for Alzeimer's disease
DK10012342.1T DK2356996T5 (da) 2003-05-08 2004-05-03 Behandling af alzheimer's sygdom
EP08170222.7A EP2075007B9 (en) 2003-05-08 2004-05-03 Treatment for Alzheimer's disease
PT04730882T PT1623719E (pt) 2003-05-08 2004-05-03 Tratamento da doença de alzheimer e da angiopatia amilóide cerebral
PL10012342T PL2356996T3 (pl) 2003-05-08 2004-05-03 Leczenie choroby Alzheimera
DK08170222.7T DK2075007T3 (da) 2003-05-08 2004-05-03 Behandling af Alzheimers sygdom
CNA2004800125340A CN1784240A (zh) 2003-05-08 2004-05-03 阿尔茨海默氏病的治疗方法
RU2005134351/15A RU2385161C2 (ru) 2003-05-08 2004-05-03 Способ лечения болезни альцгеймера
JP2006505607A JP2006525288A (ja) 2003-05-08 2004-05-03 アルツハイマー病治療方法
DE602004021797T DE602004021797D1 (de) 2003-05-08 2004-05-03 Behandlung von alzheimer-krankheit und amyloider gehirnangiopathie
EP04730882A EP1623719B1 (en) 2003-05-08 2004-05-03 Treatment of alzheimer's disease and cerebral amyloid angiopathy
PT81702227T PT2075007E (pt) 2003-05-08 2004-05-03 Tratamento para a doença de alzheimer
BRPI0410684-9A BRPI0410684A (pt) 2003-05-08 2004-05-03 uso de um peptìdio conjugado a uma proteìna que age como um imunógeno para a produção de anticorpos capazes de reconhecer especificamente qualquer uma das variantes predominantes do peptìdeo beta amilóide aß40 e aß42 na preparação de um medicamento para a prevenção e/ou o tratamento de uma doença e uso de um anticorpo ou um fragmento ativo ou o derivado de um anticorpo que reconhece especificamente qualquer uma das variantes predominantes do peptìdio beta amilóide, aß40 e aß42, na preparação de um medicamento para prevenção e/ou tratamento de uma doença
EP10012342.1A EP2356996B9 (en) 2003-05-08 2004-05-03 Treatment for Alzheimer's disease
AU2004237373A AU2004237373A1 (en) 2003-05-08 2004-05-03 Alzheimer's disease treatment method
MXPA05010914A MXPA05010914A (es) 2003-05-08 2004-05-03 Metodo de tratamiento de la enfermedad de alzheimer.
ES04730882T ES2329369T3 (es) 2003-05-08 2004-05-03 Tratamiento de la enfermedad de alzheimer y la angiopatia amiloide cerebral.
CNA2008100898940A CN101264326A (zh) 2003-05-08 2004-05-03 阿尔茨海默氏病的治疗方法
US10/555,865 US20090162362A1 (en) 2003-05-08 2004-05-03 Alzheimer's disease treatment method
PCT/ES2004/000194 WO2004098631A1 (es) 2003-05-08 2004-05-03 Método de tratamiento de la enfermedad de alzheimer
PL08170222T PL2075007T3 (pl) 2003-05-08 2004-05-03 Leczenie choroby Alzheimera
AT04730882T ATE435024T1 (de) 2003-05-08 2004-05-03 Behandlung von alzheimer-krankheit und amyloider gehirnangiopathie
EP10012340A EP2305286A3 (en) 2003-05-08 2004-05-03 Treatment for Alzeimer's disease
CA2524571A CA2524571C (en) 2003-05-08 2004-05-03 Alzheimer's disease treatment method comprising a beta-amyloid peptide
PL04730882T PL1623719T3 (pl) 2003-05-08 2004-05-03 Leczenie choroby Alzheimer´a i mózgowej angiopatii amyloidowej
PT100123421T PT2356996E (pt) 2003-05-08 2004-05-03 Tratamento para a doença de alzheimer
ES08170222T ES2423281T3 (es) 2003-05-08 2004-05-03 Tratamiento de la enfermedad de Alzheimer
SI200431235T SI1623719T1 (sl) 2003-05-08 2004-05-03 Zdravljenje Alzheimerjeve bolezni in cerebralne amiloidne angiopatije
IL171651A IL171651A (en) 2003-05-08 2005-10-27 Use of a peptide for the production of antibodies for the treatment of alzheimer's disease
CY20091101026T CY1109454T1 (el) 2003-05-08 2009-10-02 Θεραπεια για τη νοσο του αλτσχαϊμερ και της αγγειακης εγκεφαλικης αμυλοειδοπαθειας
RU2009148539/15A RU2526155C2 (ru) 2003-05-08 2009-12-25 Способ лечения болезни альцгеймера
IL207881A IL207881A (en) 2003-05-08 2010-08-30 Use of antibodies to prepare drugs to treat Alzheimer's disease
IL207876A IL207876A (en) 2003-05-08 2010-08-30 A method of treating Alzheimer's disease
IL207878A IL207878A (en) 2003-05-08 2010-08-30 Use of a peptide for the production of antibodies for the treatment of Alzheimer's disease
IL207877A IL207877A (en) 2003-05-08 2010-08-30 A method of treating Alzheimer's disease
IL207879A IL207879A (en) 2003-05-08 2010-08-30 Use of antibodies to prepare drugs to treat Alzheimer's disease
IL207875A IL207875A (en) 2003-05-08 2010-08-30 Use of antibodies to prepare drugs to treat Alzheimer's disease
IL207880A IL207880A (en) 2003-05-08 2010-08-30 Use of peptides for the production of antibodies to treat Alzheimer's disease
AU2011200170A AU2011200170C1 (en) 2003-05-08 2011-01-17 Alzheimer's disease treatment method
US13/050,654 US20110262458A1 (en) 2003-05-08 2011-03-17 Alzheimer's Disease Treatment Method
JP2011191515A JP2012006967A (ja) 2003-05-08 2011-09-02 アルツハイマー病治療方法
US14/026,374 US20140044725A1 (en) 2003-05-08 2013-09-13 Alzheimer's disease treatment method
JP2014038360A JP2014129389A (ja) 2003-05-08 2014-02-28 アルツハイマー病治療方法
JP2016003772A JP2016065100A (ja) 2003-05-08 2016-01-12 アルツハイマー病治療方法
US15/602,779 US20170260234A1 (en) 2003-05-08 2017-05-23 Alzheimer's disease treatment method
JP2018088643A JP2018119011A (ja) 2003-05-08 2018-05-02 アルツハイマー病治療方法
US16/745,067 US20200140488A1 (en) 2003-05-08 2020-01-16 Alzheimer's disease treatment method
US17/213,720 US20210214394A1 (en) 2003-05-08 2021-03-26 Alzheimer's disease treatment method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200301054A ES2246105B1 (es) 2003-05-08 2003-05-08 Uso de anticuerpos para el tratamiento de enfermedades amiloideas.

Publications (2)

Publication Number Publication Date
ES2246105A1 ES2246105A1 (es) 2006-02-01
ES2246105B1 true ES2246105B1 (es) 2007-03-01

Family

ID=32982086

Family Applications (6)

Application Number Title Priority Date Filing Date
ES200301054A Expired - Fee Related ES2246105B1 (es) 2003-05-08 2003-05-08 Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
ES200403158A Expired - Fee Related ES2246177B1 (es) 2003-05-08 2003-05-08 Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
ES200403159A Expired - Fee Related ES2246178B1 (es) 2003-05-08 2003-05-08 Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
ES08170222T Expired - Lifetime ES2423281T3 (es) 2003-05-08 2004-05-03 Tratamiento de la enfermedad de Alzheimer
ES10012342T Expired - Lifetime ES2423590T3 (es) 2003-05-08 2004-05-03 Tratamiento de la enfermedad de Alzheimer
ES04730882T Expired - Lifetime ES2329369T3 (es) 2003-05-08 2004-05-03 Tratamiento de la enfermedad de alzheimer y la angiopatia amiloide cerebral.

Family Applications After (5)

Application Number Title Priority Date Filing Date
ES200403158A Expired - Fee Related ES2246177B1 (es) 2003-05-08 2003-05-08 Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
ES200403159A Expired - Fee Related ES2246178B1 (es) 2003-05-08 2003-05-08 Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
ES08170222T Expired - Lifetime ES2423281T3 (es) 2003-05-08 2004-05-03 Tratamiento de la enfermedad de Alzheimer
ES10012342T Expired - Lifetime ES2423590T3 (es) 2003-05-08 2004-05-03 Tratamiento de la enfermedad de Alzheimer
ES04730882T Expired - Lifetime ES2329369T3 (es) 2003-05-08 2004-05-03 Tratamiento de la enfermedad de alzheimer y la angiopatia amiloide cerebral.

Country Status (19)

Country Link
US (6) US20090162362A1 (https=)
EP (5) EP2305286A3 (https=)
JP (5) JP2006525288A (https=)
CN (2) CN1784240A (https=)
AT (1) ATE435024T1 (https=)
AU (2) AU2004237373A1 (https=)
BR (1) BRPI0410684A (https=)
CA (1) CA2524571C (https=)
CY (1) CY1109454T1 (https=)
DE (1) DE602004021797D1 (https=)
DK (3) DK2356996T5 (https=)
ES (6) ES2246105B1 (https=)
IL (8) IL171651A (https=)
MX (1) MXPA05010914A (https=)
PL (3) PL2075007T3 (https=)
PT (3) PT1623719E (https=)
RU (2) RU2385161C2 (https=)
SI (1) SI1623719T1 (https=)
WO (1) WO2004098631A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
ES2246105B1 (es) * 2003-05-08 2007-03-01 Araclon Biotech, S.L. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
BRPI0513959A (pt) 2004-07-30 2008-05-20 Rinat Neuroscience Corp anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
SG10201404801YA (en) 2005-12-12 2014-09-26 Ac Immune Sa Monoclonal antibody
NZ574188A (en) * 2006-07-14 2012-05-25 Ac Immune Sa Humanized antibody against amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) * 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
SG178809A1 (en) * 2007-10-05 2012-03-29 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
RS53174B (sr) * 2007-10-05 2014-06-30 Genentech Inc. Upotreba antiamiloidnog beta antitela u slučaju oboljenja oka
EP2149380A1 (en) * 2008-07-29 2010-02-03 Medivet Pharma, S.L. Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction.
EP2258398A1 (en) 2009-05-26 2010-12-08 Araclón Biotech, S. L. Albumin-amyloid peptide conjugates and uses thereof
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
WO2011070174A1 (en) 2009-12-11 2011-06-16 Araclon Biotech, S.L. Methods and reagents for improved detection of amyloid beta peptides
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
CA2805414C (en) * 2010-07-14 2020-07-07 Merck Sharp & Dohme Corp. Anti-addl monoclonal antibody and uses thereof
RU2607368C2 (ru) * 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
EP3027205A4 (en) 2013-07-28 2017-07-19 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
ES2571055B1 (es) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Conjugado amiloide y usos y procedimientos del mismo
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
PL237739B1 (pl) 2018-06-06 2021-05-17 Univ Gdanski Genisteina do zastosowania do leczenia choroby Alzheimera
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027944A1 (en) * 1997-12-02 1999-06-10 Neuralab Limited Prevention and treatment of amyloidogenic disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339014C (en) * 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
AU5525090A (en) * 1989-04-14 1990-11-16 Research Foundation For Mental Hygiene, Inc. Monoclonal antibody to amyloid peptide
ATE153534T1 (de) 1990-04-27 1997-06-15 John Mcmichael Verfahren und zusammensetzung zur behandlung von erkrankungen des zns hervorgerufen durch abnormales beta-amyloid-protein
EP0683234B2 (en) * 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Antibody against beta-amyloid or their derivative and use thereof
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6905686B1 (en) * 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
CA2340394A1 (en) * 1998-08-20 2000-03-02 Jorge R. Barrio Methods for labeling .beta.-amyloid plaques and neurofibrillary tangles
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
EP1975179A1 (en) * 2001-12-26 2008-10-01 Araclon Biotech, S.L. Polyclonal antibodies, preparation method thereof and use of same
EP1371986A1 (en) * 2002-06-06 2003-12-17 ABETA GmbH Diagnosis of Alzheimer's disease based on the hAbeta42:hAbeta40 ratio
CA2487528A1 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
ES2201929B1 (es) * 2002-09-12 2005-05-16 Araclon Biotech, S.L. Anticuerpos policlonales, metodo de preparacion y uso de los mismos.
MXPA05003621A (es) * 2002-10-09 2005-10-19 Rinat Neuroscience Corp Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos.
MXPA05008156A (es) * 2003-02-01 2005-09-30 Neuralab Ltd Inmunizacion activa para generar anticuerpos para beta-a soluble.
ES2246105B1 (es) * 2003-05-08 2007-03-01 Araclon Biotech, S.L. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027944A1 (en) * 1997-12-02 1999-06-10 Neuralab Limited Prevention and treatment of amyloidogenic disease

Also Published As

Publication number Publication date
US20170260234A1 (en) 2017-09-14
DK2356996T5 (da) 2013-08-26
EP1623719B1 (en) 2009-07-01
IL207876A0 (en) 2011-07-31
ES2246178B1 (es) 2007-03-01
IL207877A (en) 2013-03-24
ES2246105A1 (es) 2006-02-01
US20110262458A1 (en) 2011-10-27
RU2005134351A (ru) 2006-04-27
IL207881A0 (en) 2011-07-31
EP2305286A3 (en) 2011-11-09
EP1623719A1 (en) 2006-02-08
PT2075007E (pt) 2013-08-23
SI1623719T1 (sl) 2009-12-31
ES2423590T3 (es) 2013-09-23
IL207879A (en) 2013-02-28
JP2012006967A (ja) 2012-01-12
RU2009148539A (ru) 2011-06-27
EP2356996B9 (en) 2013-08-28
BRPI0410684A (pt) 2006-06-20
EP2356996B1 (en) 2013-06-26
JP2014129389A (ja) 2014-07-10
PL1623719T3 (pl) 2010-11-30
EP2305286A2 (en) 2011-04-06
IL207877A0 (en) 2011-07-31
ES2329369T3 (es) 2009-11-25
EP2075007B1 (en) 2013-05-22
AU2011200170B2 (en) 2011-09-01
ES2423281T3 (es) 2013-09-19
IL207879A0 (en) 2011-07-31
IL207875A (en) 2013-02-28
IL207880A0 (en) 2011-07-31
ES2246178A1 (es) 2006-02-01
JP2016065100A (ja) 2016-04-28
DK2075007T3 (da) 2013-07-29
RU2385161C2 (ru) 2010-03-27
CN1784240A (zh) 2006-06-07
ES2246177A1 (es) 2006-02-01
DK2356996T3 (da) 2013-07-22
PL2356996T3 (pl) 2013-09-30
US20200140488A1 (en) 2020-05-07
DK1623719T3 (da) 2009-11-09
CN101264326A (zh) 2008-09-17
ES2246177B1 (es) 2007-03-01
ATE435024T1 (de) 2009-07-15
EP2356996A1 (en) 2011-08-17
AU2011200170C1 (en) 2012-03-22
EP2075007A2 (en) 2009-07-01
CA2524571C (en) 2017-01-10
PL2075007T3 (pl) 2013-09-30
MXPA05010914A (es) 2006-03-21
WO2004098631A1 (es) 2004-11-18
US20090162362A1 (en) 2009-06-25
EP2082747A3 (en) 2010-01-13
DE602004021797D1 (de) 2009-08-13
PT1623719E (pt) 2009-10-08
CY1109454T1 (el) 2014-08-13
EP2082747A2 (en) 2009-07-29
IL207878A0 (en) 2011-07-31
PT2356996E (pt) 2013-08-23
IL207875A0 (en) 2011-07-31
AU2004237373A1 (en) 2004-11-18
US20140044725A1 (en) 2014-02-13
JP2006525288A (ja) 2006-11-09
CA2524571A1 (en) 2004-11-18
IL171651A (en) 2011-11-30
RU2526155C2 (ru) 2014-08-20
IL207876A (en) 2013-03-24
AU2011200170A1 (en) 2011-02-03
JP2018119011A (ja) 2018-08-02
IL207881A (en) 2013-02-28
US20210214394A1 (en) 2021-07-15
IL207878A (en) 2013-02-28
EP2075007A3 (en) 2009-11-11
IL207880A (en) 2013-02-28
EP2075007B9 (en) 2013-09-04

Similar Documents

Publication Publication Date Title
ES2246105B1 (es) Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
AU2011226926A1 (en) Alzheimer's disease treatment method

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20060201

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2246105B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20211117